Novartis will seek a review of the Federal Circuit’s decision regarding a multiple sclerosis treatment.
The European Medicines Agency has decided that medicines approved as biosimilars may be prescribed interchangeably, without the need for additional studies.
The IP law firm has expanded its life sciences team with the appointment of James Bergus, who joins from the Federal Court of Australia.
Safe harbour provisions can be relied on but their boundaries are still being defined, explain Jeanna Wacker and Tasha Francis Gerasimow of Kirkland & Ellis.
IP law firm Powell Gilbert has expanded its life sciences team with the appointment of James Bergus.